Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Open Access
- 6 July 2017
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 130 (1), 48-58
- https://doi.org/10.1182/blood-2016-04-711820
Abstract
Key Points. Polyclonal mechanisms of resistance, demonstrated by single-cell analysis, occur in the majority of AML patients who relapse on quizartinib.Keywords
This publication has 41 references indexed in Scilit:
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencingNature, 2012
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Enhanced growth of myelodysplastic colonies in hypoxic conditionsExperimental Hematology, 2007